Treatment-Refractory, Primary Immune Thrombocytopenic Purpura in a Patient with Celiac Disease.
Journal
The American journal of case reports
ISSN: 1941-5923
Titre abrégé: Am J Case Rep
Pays: United States
ID NLM: 101489566
Informations de publication
Date de publication:
10 Oct 2021
10 Oct 2021
Historique:
entrez:
10
10
2021
pubmed:
11
10
2021
medline:
13
10
2021
Statut:
epublish
Résumé
BACKGROUND Immune thrombocytopenic purpura (ITP) is primarily caused by antibody-mediated destruction of platelets. Alterations in immune homeostasis can induce loss of peripheral tolerance and promote the development of self-reactive antibodies. Primary ITP is the diagnosis of exclusion made after the extensive work-up rules out other possible causes of thrombocytopenia. The association between the ITP and other autoimmune disorders is well-established. In recent years, increasing attention has been directed toward the association between celiac disease (CD) and ITP. CASE REPORT A 27-year-old man with a history of primary ITP presented with an occasional nosebleed, 1 episode of rectal bleeding, and easy bruising. The patient was later found to have high titers of TTG-IGA and endomysial IGA levels consistent with CD. Our patient not only failed to improve with the gluten-free diet, but also failed multiple lines of treatment including steroids, IVIG, rituximab, eltrombopag, and even a non-traditional treatment for ITP (azathioprine and plasma exchange). The patient's CD-related antibody titers remained elevated. CONCLUSIONS It is possible that in certain cases the alteration of immune response caused by CD with a concurrent elevation of CD-related antibodies can make ITP refractory to all medical management. Whether or not this refractoriness to treatment is related to the persistently elevated antibody titers of CD or unknown genetic relationship between ITP and CD remains not entirely clear and warrants further molecular, immunologic, and genetic analysis.
Identifiants
pubmed: 34628462
pii: 931877
doi: 10.12659/AJCR.931877
pmc: PMC8515496
doi:
Substances chimiques
Rituximab
4F4X42SYQ6
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e931877Références
PLoS Med. 2006 Sep;3(9):e358
pubmed: 16984219
J Invest Dermatol. 2002 Aug;119(2):392-402
pubmed: 12190862
Acta Paediatr Scand. 1988 Sep;77(5):764-6
pubmed: 3201985
Arch Intern Med. 1982 May;142(5):1037
pubmed: 7200763
Clin Cosmet Investig Dermatol. 2015 Jul 24;8:397-403
pubmed: 26244028
Clin Appl Thromb Hemost. 2011 Nov-Dec;17(6):E13-6
pubmed: 20682594
Scand J Gastroenterol. 2008;43(4):416-22
pubmed: 18365906
Gastroenterol Res Pract. 2018 Apr 23;2018:4138434
pubmed: 29849587
Case Rep Hematol. 2017;2017:6341321
pubmed: 28424750
Blood. 2006 Jan 15;107(2):637-41
pubmed: 16179373
Nat Rev Dis Primers. 2017 Mar 16;3:17011
pubmed: 28300084
Hum Immunol. 2006 Jun;67(6):460-8
pubmed: 16728270